In a first for the U.S. Food and Drug Administration (FDA), the genetic testing company 23andMe is being given permission to sell genetic tests for disease risks.
23andMe, known for their ancestral genetic tests, will now be able to sell genetics tests capable to analyzing a person disease risk for developing 10 different conditions including Parkinson’s and Alzheimer’s. The decision is set to open the genetic testing market to other companies, increasing the rate of at-home testing for risk of disease development.
Read the full story by clicking below:
Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.